Market Overview

Teva Reports Q4 Earnings Beat

Share:
Teva Reports Q4 Earnings Beat

Teva Pharmaceutical Indus (NYSE: TEVA) reported fourth-quarter earnings of 64 cents per share, which beat the analyst consensus estimate of 61 cents by 4.92%. This is a 20.75% increase over earnings of 53 cents per share from the same period last year.

The company reported quarterly sales of $4.5 billion, which beat the analyst consensus estimate of $4.35 billion by 3.45%. This is a 1.29% decrease over sales of $4.559 billion the same period last year.

Teva sees fiscal year 2020 adjusted EPS $2.30-$2.55 versus the $2.47 estimate and sales at $16.6-$17 billion versus the $17.18 billion estimate.

"In 2019, we made great strides towards positioning Teva for renewed growth by completing our two-year restructuring plan, reducing our cost base by more than $3 billion, and reducing our net debt by more than $9 billion, all while maintaining our global leadership in generics, serving around 200 million patients every day," said CEO Kåre Schultz.

Teva shares were trading up 3% at $12.72 in Wednesday’s pre-market session. The stock has a 52-week high of $19.21 and a 52-week low of $6.07.

Posted-In: Earnings News Guidance Best of Benzinga

 

Related Articles (TEVA)

View Comments and Join the Discussion!
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com